# Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

> **NCT05847569** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 62 (estimated)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Belantamab Mafodotin
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspirate
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05847569
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-04
- **Primary completion:** 2029-06-29
- **Final completion:** 2034-06-29
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05847569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05847569, "Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05847569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*